ATE453402T1 - Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis - Google Patents

Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis

Info

Publication number: ATE453402T1
Authority: AT; Austria
Prior art keywords: serp; combination; immunosuppressor; compositions; methods
Prior art date: 2000-09-29

Application number

AT01971584T

Other languages

English (en)

Inventor

Robert Z Zhong

Alexandra Lucas

Grant D Mcfadden

Original Assignee

Viron Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-29

Filing date

2001-09-28

Publication date

2010-01-15

2001-09-28 Application filed by Viron Therapeutics Inc filed Critical Viron Therapeutics Inc

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE453402T1 publication Critical patent/ATE453402T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT01971584T 2000-09-29 2001-09-28 Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis ATE453402T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23693900P	2000-09-29	2000-09-29
PCT/CA2001/001369 WO2002026245A2 (en)	2000-09-29	2001-09-28	Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions

Publications (1)

Publication Number	Publication Date
ATE453402T1 true ATE453402T1 (de)	2010-01-15

Family

ID=22891637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01971584T ATE453402T1 (de)	2000-09-29	2001-09-28	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis

Country Status (8)

Country	Link
US (1)	US7419670B2 (de)
EP (1)	EP1365798B1 (de)
JP (1)	JP2004509171A (de)
AT (1)	ATE453402T1 (de)
AU (2)	AU2001291579B2 (de)
CA (1)	CA2423313A1 (de)
DE (1)	DE60140960D1 (de)
WO (1)	WO2002026245A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1123001A (en)	1999-10-27	2001-05-08	Alexandra Lucas	Compositions and methods for preventing and treating transplant rejection
AU2001291579B2 (en)	2000-09-29	2006-08-31	Viron Therapeutics Inc.	Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
AU2003280252A1 (en) *	2002-11-01	2004-05-25	Alexandra R. Lucas	Viral serpin regulation of inflamation
FR2849598B1 (fr) *	2003-01-07	2006-09-22	Merck Sante Sas	Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US7285530B2 (en)	2004-10-21	2007-10-23	Viron Therapeutics, Inc.	Use of SERP-1 as an antiplatelet agent
EP2023948A1 (de) *	2006-05-04	2009-02-18	Michel Ovize	Verwendung von cyclosporin a oder melle4-cyclosporin zur behandlung von akutem myokardinfarkt
US8251876B2 (en)	2008-04-22	2012-08-28	Hill-Rom Services, Inc.	Breathing exercise apparatus
US20130203650A1 (en)	2010-08-31	2013-08-08	Yissum Research Development Company Of The Hebrew Uviversity Of Jerusalem	Polypeptides derived from alpha-1 antitrypsin and methods of use thereof
US9518107B2 (en)	2010-08-31	2016-12-13	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
WO2012103520A1 (en) *	2011-01-28	2012-08-02	Board Of Regents Of The University Of Nebraska	Methods and compositions for modulating cyclophilin d
US9180271B2 (en)	2012-03-05	2015-11-10	Hill-Rom Services Pte. Ltd.	Respiratory therapy device having standard and oscillatory PEP with nebulizer
HRP20231163T1 (hr)	2015-07-31	2024-03-15	The Johns Hopkins University	Prolijekovi glutaminskih analoga
US10842763B2 (en)	2015-07-31	2020-11-24	The Johns Hopkins University	Methods for cancer and immunotherapy using prodrugs of glutamine analogs
EP3328376A4 (de)	2015-07-31	2019-03-13	The Johns Hopkins University	Verfahren und zusammensetzung zur behandlung metabolischer umprogrammierungserkrankungen
US11185534B2 (en)	2017-02-01	2021-11-30	The Johns Hopkins University	Prodrugs of glutamine analogs
EP3911351A4 (de) *	2019-01-14	2022-10-19	Arizona Board of Regents on behalf of Arizona State University	Serinproteinasehemmer: wirkung von serp-1- und serp-1-rcl-derivierten peptiden auf mikrobiomzusammensetzung und deren verwendungen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206017A (en)	1986-06-03	1993-04-27	Incyte Pharmaceuticals, Inc.	Use of protease nexin-I as an antiinflammatory
DE3829523A1 (de)	1988-08-31	1990-03-01	Behringwerke Ag	Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
GB9007971D0 (en)	1990-04-09	1990-06-06	Imutran Ltd	Pharmaceutical formulations
EP0512090B2 (de)	1990-10-16	2006-11-22	Sonoran Desert Chemicals LLC	Behandlung von entzündungen
WO1992022320A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4214215A1 (de)	1992-04-30	1993-11-04	Behringwerke Ag	Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
WO1995027503A1 (en)	1994-04-08	1995-10-19	Mcfadden D Grant	Antirestenosis protein
US5624946A (en) *	1994-07-05	1997-04-29	Williams; James	Use of leflunomide to control and reverse chronic allograft rejection
US5939525A (en) *	1995-03-27	1999-08-17	Viron Therapeutics, Inc.	Methods of treating inflammation and compositions therefor
CA2231804A1 (en) *	1995-09-11	1997-03-20	University Of Florida Research Foundation, Inc.	Method for inhibiting cell-mediated killing of target cells
GB9811854D0 (en) *	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
EP0982035B1 (de)	1998-08-18	2004-03-31	Panacea Biotec Limited	Zusammensetzung enthalten Cyclsoporin in einem hydrophilen Träger
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2000053793A1 (en) *	1999-03-10	2000-09-14	Human Genome Sciences, Inc.	Brain-associated inhibitor of tissue-type plasminogen activator
AU1123001A (en) *	1999-10-27	2001-05-08	Alexandra Lucas	Compositions and methods for preventing and treating transplant rejection
US6428308B1 (en)	1999-11-29	2002-08-06	Honeywell Inc.	Electronic fuel convertibility selection
WO2001039790A1 (en)	1999-12-02	2001-06-07	Viron Therapeutics, Inc.	Methods of treating inflammation and compositions therefor
AU2001291579B2 (en)	2000-09-29	2006-08-31	Viron Therapeutics Inc.	Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
AU2003280252A1 (en)	2002-11-01	2004-05-25	Alexandra R. Lucas	Viral serpin regulation of inflamation
US7285530B2 (en) *	2004-10-21	2007-10-23	Viron Therapeutics, Inc.	Use of SERP-1 as an antiplatelet agent

2001
- 2001-09-28 AU AU2001291579A patent/AU2001291579B2/en not_active Ceased
- 2001-09-28 WO PCT/CA2001/001369 patent/WO2002026245A2/en not_active Ceased
- 2001-09-28 DE DE60140960T patent/DE60140960D1/de not_active Expired - Lifetime
- 2001-09-28 US US10/381,875 patent/US7419670B2/en not_active Expired - Fee Related
- 2001-09-28 JP JP2002530075A patent/JP2004509171A/ja active Pending
- 2001-09-28 AT AT01971584T patent/ATE453402T1/de not_active IP Right Cessation
- 2001-09-28 EP EP01971584A patent/EP1365798B1/de not_active Expired - Lifetime
- 2001-09-28 CA CA002423313A patent/CA2423313A1/en not_active Abandoned
- 2001-09-28 AU AU9157901A patent/AU9157901A/xx active Pending

Also Published As

Publication number	Publication date
CA2423313A1 (en)	2002-04-04
AU2001291579B2 (en)	2006-08-31
EP1365798A2 (de)	2003-12-03
DE60140960D1 (de)	2010-02-11
US20040029801A1 (en)	2004-02-12
AU9157901A (en)	2002-04-08
JP2004509171A (ja)	2004-03-25
WO2002026245A3 (en)	2003-10-09
WO2002026245A2 (en)	2002-04-04
EP1365798B1 (de)	2009-12-30
US7419670B2 (en)	2008-09-02

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE453402T1 (de)	2010-01-15	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE328605T1 (de)	2006-06-15	Verwendung von insulin zur behandlung von knorpelkrankheiten
ATE309802T1 (de)	2005-12-15	Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69733132D1 (de)	2005-06-02	Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE60037394D1 (de)	2008-01-24	VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE510542T1 (de)	2011-06-15	Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60320770D1 (de)	2008-06-19	Verfahren zur verabreichung von buprenorphin zur behandlung von depression
ATE230609T1 (de)	2003-01-15	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE281841T1 (de)	2004-11-15	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE297739T1 (de)	2005-07-15	Endothelin-antagonisten zur behandlung von herzversagen
DE69818809D1 (de)	2003-11-13	Verfahren zur behandlung von narbengewebe
DE69623316D1 (de)	2002-10-02	Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE268170T1 (de)	2004-06-15	Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE369143T1 (de)	2007-08-15	Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE236633T1 (de)	2003-04-15	Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
NO984196D0 (no)	1998-09-11	Fremgangsmåte for behandling av stoffmisbruk
DE69635282D1 (de)	2006-02-23	Behandlung der exzessiven aggressivität mit olanzapine
ATE291434T1 (de)	2005-04-15	Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE345138T1 (de)	2006-12-15	Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen